Safety and feasibility of NeuroFlo use in eight- to 24-hour ischemic stroke patients. - Wikidata - awgldk - TriplyDB

Safety and feasibility of NeuroFlo use in eight- to 24-hour ischemic stroke patients.

Safety and feasibility of NeuroFlo use in eight- to 24-hour ischemic stroke patients.

http://www.wikidata.org/entity/Q34150303

about

Ischemia-reperfusion injury in stroke Effects of age on outcome in the SENTIS trial: better outcomes in elderly patients.Reduced mortality and severe disability rates in the SENTIS trial.Vascular remodeling after ischemic stroke: mechanisms and therapeutic potentials Flow Augmentation in Acute Ischemic Stroke.Statistical analysis plan of the head position in acute ischemic stroke trial pilot (HEADPOST pilot).Collateral blood vessels in acute ischemic stroke: a physiological window to predict future outcomes.

P2860

Q33653045-EA199463-76D8-4F40-9CFB-81C0A9E5EDB1 Q34088454-86346DA4-CC84-4F70-8149-689E43885B95 Q34143609-BEC2F847-E56E-4390-9B97-A5D7EBC6C1E5 Q34972793-E5EF5BBC-2481-444B-AD91-681FF52EB82F Q35490685-24C3B327-30C4-4964-AD2B-82FA64776D70 Q38386577-CAA99C72-8643-4756-AB08-DF946C5F6BCD Q38844105-FC742A88-1FF3-40BE-AB50-95539CEB7B6E

P2860

Safety and feasibility of NeuroFlo use in eight- to 24-hour ischemic stroke patients.

http://www.wikidata.org/entity/Q34150303

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Safety and feasibility of NeuroFlo use in eight- to 24-hour ischemic stroke patients.

@ast

Safety and feasibility of NeuroFlo use in eight- to 24-hour ischemic stroke patients.

@en

Safety and feasibility of NeuroFlo use in eight- to 24-hour ischemic stroke patients.

@nl

type

label

Safety and feasibility of NeuroFlo use in eight- to 24-hour ischemic stroke patients.

@ast

Safety and feasibility of NeuroFlo use in eight- to 24-hour ischemic stroke patients.

@en

Safety and feasibility of NeuroFlo use in eight- to 24-hour ischemic stroke patients.

@nl

prefLabel

Safety and feasibility of NeuroFlo use in eight- to 24-hour ischemic stroke patients.

@ast

Safety and feasibility of NeuroFlo use in eight- to 24-hour ischemic stroke patients.

@en

Safety and feasibility of NeuroFlo use in eight- to 24-hour ischemic stroke patients.

@nl

P1433

Q34150303-A00A2338-C1C9-490E-9BA0-5340C93C996E

P1476

Q34150303-60FB2EFE-7C47-4A95-8DB4-097F48F4C94E

P2093

Q34150303-01ED5A97-DF52-4537-A06E-C29258DCCBEB

Q34150303-20C1E323-BA1D-4E2E-BD23-1F65FAFE2002

Q34150303-26DC870A-86F0-48EC-A560-E2E302F20004

Q34150303-2917988D-29B9-49E2-8AC8-E14EAB4BF90E

Q34150303-3C0C5D28-5D27-422B-BDE2-65C4AADB8FDE

Q34150303-5D1C67A1-A6A4-486E-9227-0F7CF4620062

Q34150303-68AB3F1F-B5CE-421F-9CD2-48998CFD53B7

Q34150303-6C50AF56-BC41-4AAC-B852-8812BC4254CA

Q34150303-6E579193-E267-4664-ADEF-61A7B1F4BB09

Q34150303-75607F06-6F24-41C1-A2F6-2A586737BB10

P2860

Q34150303-0FAA35BF-290D-4D60-AAC2-364CD6D841F4

Q34150303-1BF51DA6-8B8B-45FC-B6D4-3E56256E7CE2

Q34150303-30F85856-5556-4ABF-B51C-EBAF9BC7A890

Q34150303-4A08C0DC-5B78-423F-BD3A-55DC5B3880A6

Q34150303-86508A8D-5045-4A85-8A27-82E5D90AFB94

Q34150303-89DB04C1-FFFB-4A21-8ABF-5AC68FF3153E

Q34150303-8E33AD40-F30D-4147-A7BB-0D7FEBF27957

Q34150303-91751B4E-57E6-4081-894C-67979B5BA60E

Q34150303-9F6672AB-F83B-4FEA-8B4B-972D9FD93487

Q34150303-B2FA4458-F1BC-41D0-BD73-A71FDD9B61C3

P304

Q34150303-6E327C34-1461-44AC-B038-E4F2DDAFE791

P31

Q34150303-054A971A-DE0E-41D4-B1F5-F2F02D7B8A26

P356

Q34150303-EBCE92B3-1886-4297-B498-D1B883614C0C

P433

Q34150303-A864C851-2EEC-4AFB-B00F-C37B7CB7B8E7

P478

Q34150303-B9DB6F56-8ABA-4E67-AD61-1E117E2C9333

P50

Q34150303-68833880-EEE7-4C53-A68D-FCD5E40FE625

Q34150303-D7F0A456-6600-46DC-B811-C78723C2F0E3

P577

Q34150303-1890CCAA-4CCF-4D7B-91B3-44DBC1F6B0E2

P698

Q34150303-E79E67A2-BB6A-482C-95BC-6231EB3C7F1D

P932

Q34150303-FDC240E4-D9FD-4317-BE06-C15674335B05

P356

J.1747-4949.2011.00719.X

P1433

International Journal of Stroke

P1476

Safety and feasibility of NeuroFlo use in eight- to 24-hour ischemic stroke patients

@en

P2093

A Shuaib

http://www.w3.org/2001/XMLSchema#string

D S Liebeskind

http://www.w3.org/2001/XMLSchema#string

H C Diener

http://www.w3.org/2001/XMLSchema#string

M D Hammer

http://www.w3.org/2001/XMLSchema#string

P D Schellinger

http://www.w3.org/2001/XMLSchema#string

P Michel

http://www.w3.org/2001/XMLSchema#string

R Nogueira

http://www.w3.org/2001/XMLSchema#string

S Sen

http://www.w3.org/2001/XMLSchema#string

S Starkman

http://www.w3.org/2001/XMLSchema#string

T Jovin

http://www.w3.org/2001/XMLSchema#string

P2860

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke

Tissue plasminogen activator for acute ischemic stroke

Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials

Collaterals in acute stroke: beyond the clot.

Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Collateral therapeutics for cerebral ischemia.

Aortic occlusion for cerebral ischemia: from theory to practice.

Endovascular approaches to acute stroke, part 2: a comprehensive review of studies and trials.

Enhancement of cerebral flood flow by intermittent aortic occlusion.

Partial intra-aortic occlusion improves perfusion deficits and infarct size following focal cerebral ischemia.

P304

655-661

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1747-4949.2011.00719.X

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-01-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22264202

http://www.w3.org/2001/XMLSchema#string

P932

4157918

http://www.w3.org/2001/XMLSchema#string